New "gene therapy" for $4M/treatment approved for an "ultra rare" "genetic" condition
Laundering of vaccine injuries for gaslighting and profit
According to the Endpoint News:
Orchard Therapeutics’ ultra-rare disease drug Lenmeldy is vaulting to the list of most expensive drugs ever with a wholesale acquisition cost of $4.25 million for the one-time treatment in the US.
The company announced the price Wednesday following Lenmeldy’s FDA approval earlier this week, saying that it reflects “its clin…
Keep reading with a 7-day free trial
Subscribe to Due Diligence and Art to keep reading this post and get 7 days of free access to the full post archives.